http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 13 Jul 2026 08:01:10 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/FDA/CEL-SCI+launches+phase+3+confirmatory+study+for+head+and+neck+cancer+drug/26760108.html <p>CEL-SCI Corporation (NYSE American: CVM) announced it is launching a global confirmatory registration study of its investigational drug Multikine (Leukocyte Interleukin, Injection) as a neoadjuvant treatment for newly diagnosed, previously untreated, resectable, locally advanced head and neck cancer.</p> <p>The study will enroll approximately 212 patients across clinical centers in the United States, Europe, Asia, and South America. Orient EuroPharma, CEL-SCI's partner in Taiwan, will oversee and fund enrollment within its territory.</p> <p>The study targets patients with squamous cell carcinoma of the head and neck whose tumors show low or zero PD-L1 expression and no clinical lymph node involvement. This cohort reflects a http://www.streetinsider.com/FDA/CEL-SCI+launches+phase+3+confirmatory+study+for+head+and+neck+cancer+drug/26760108.html Mon, 13 Jul 2026 08:01:10 -0400 A.06822034 CVM O.02168038 O.20026344 http://www.streetinsider.com/FDA/CEL-SCI+launches+phase+3+confirmatory+study+for+head+and+neck+cancer+drug/26760108.html <p>CEL-SCI Corporation (NYSE American: CVM) announced it is launching a global confirmatory registration study of its investigational drug Multikine (Leukocyte Interleukin, Injection) as a neoadjuvant treatment for newly diagnosed, previously untreated, resectable, locally advanced head and neck cancer.</p> <p>The study will enroll approximately 212 patients across clinical centers in the United States, Europe, Asia, and South America. Orient EuroPharma, CEL-SCI's partner in Taiwan, will oversee and fund enrollment within its territory.</p> <p>The study targets patients with squamous cell carcinoma of the head and neck whose tumors show low or zero PD-L1 expression and no clinical lymph node involvement. This cohort reflects a http://www.streetinsider.com/FDA/CEL-SCI+launches+phase+3+confirmatory+study+for+head+and+neck+cancer+drug/26760108.html Mon, 13 Jul 2026 08:01:10 -0400 A.06822034 CVM O.02168038 O.20026344 http://www.streetinsider.com/FDA/CEL-SCI+launches+phase+3+confirmatory+study+for+head+and+neck+cancer+drug/26760108.html <p>CEL-SCI Corporation (NYSE American: CVM) announced it is launching a global confirmatory registration study of its investigational drug Multikine (Leukocyte Interleukin, Injection) as a neoadjuvant treatment for newly diagnosed, previously untreated, resectable, locally advanced head and neck cancer.</p> <p>The study will enroll approximately 212 patients across clinical centers in the United States, Europe, Asia, and South America. Orient EuroPharma, CEL-SCI's partner in Taiwan, will oversee and fund enrollment within its territory.</p> <p>The study targets patients with squamous cell carcinoma of the head and neck whose tumors show low or zero PD-L1 expression and no clinical lymph node involvement. This cohort reflects a http://www.streetinsider.com/FDA/CEL-SCI+launches+phase+3+confirmatory+study+for+head+and+neck+cancer+drug/26760108.html Mon, 13 Jul 2026 08:01:10 -0400 A.06822034 CVM O.02168038 O.20026344 http://www.streetinsider.com/FDA/CEL-SCI+launches+phase+3+confirmatory+study+for+head+and+neck+cancer+drug/26760108.html <p>CEL-SCI Corporation (NYSE American: CVM) announced it is launching a global confirmatory registration study of its investigational drug Multikine (Leukocyte Interleukin, Injection) as a neoadjuvant treatment for newly diagnosed, previously untreated, resectable, locally advanced head and neck cancer.</p> <p>The study will enroll approximately 212 patients across clinical centers in the United States, Europe, Asia, and South America. Orient EuroPharma, CEL-SCI's partner in Taiwan, will oversee and fund enrollment within its territory.</p> <p>The study targets patients with squamous cell carcinoma of the head and neck whose tumors show low or zero PD-L1 expression and no clinical lymph node involvement. This cohort reflects a http://www.streetinsider.com/FDA/CEL-SCI+launches+phase+3+confirmatory+study+for+head+and+neck+cancer+drug/26760108.html Mon, 13 Jul 2026 08:01:10 -0400 A.06822034 CVM O.02168038 O.20026344 http://www.streetinsider.com/Press+Releases/CEL-SCI+to+Launch+FDA+Registration-Enabling+Phase+3+Confirmatory+Study+to+Bring+Multikine%C2%AE+to+Market+for+Newly+Diagnosed+Head+and+Neck+Cancer/26760011.html <ul class="bwlistdisc"> <li> <i>Patient enrollment expected to commence at clinical centers in the U.S., Europe, Asia and later on in South America</i> </li> <li> <i>The 212-patient confirmatory study is powered at approximately 97% to confirm a previously observed 0.34 hazard ratio, representing a 66% reduction in the risk of death</i> </li> <li> <i>In the target population, Multikine followed by standard of care increased the 5-year survival rate to 73% versus 45% with standard of care alone</i> </li> <li> <i>Pre-surgical tumor responses will be assessed and may serve as the basis for an early conditional or accelerated approval application with the FDA</i> </li> </ul> <p> VIENNA, Va.--(BUSINESS WIRE)-- CEL-SCI Corporation <b>(NYSE American: CVM)</b> http://www.streetinsider.com/Press+Releases/CEL-SCI+to+Launch+FDA+Registration-Enabling+Phase+3+Confirmatory+Study+to+Bring+Multikine%C2%AE+to+Market+for+Newly+Diagnosed+Head+and+Neck+Cancer/26760011.html Mon, 13 Jul 2026 08:00:00 -0400 A.06822034 CVM O.02168038 O.20026344 http://www.streetinsider.com/Press+Releases/CEL-SCI+to+Launch+FDA+Registration-Enabling+Phase+3+Confirmatory+Study+to+Bring+Multikine%C2%AE+to+Market+for+Newly+Diagnosed+Head+and+Neck+Cancer/26760011.html <ul class="bwlistdisc"> <li> <i>Patient enrollment expected to commence at clinical centers in the U.S., Europe, Asia and later on in South America</i> </li> <li> <i>The 212-patient confirmatory study is powered at approximately 97% to confirm a previously observed 0.34 hazard ratio, representing a 66% reduction in the risk of death</i> </li> <li> <i>In the target population, Multikine followed by standard of care increased the 5-year survival rate to 73% versus 45% with standard of care alone</i> </li> <li> <i>Pre-surgical tumor responses will be assessed and may serve as the basis for an early conditional or accelerated approval application with the FDA</i> </li> </ul> <p> VIENNA, Va.--(BUSINESS WIRE)-- CEL-SCI Corporation <b>(NYSE American: CVM)</b> http://www.streetinsider.com/Press+Releases/CEL-SCI+to+Launch+FDA+Registration-Enabling+Phase+3+Confirmatory+Study+to+Bring+Multikine%C2%AE+to+Market+for+Newly+Diagnosed+Head+and+Neck+Cancer/26760011.html Mon, 13 Jul 2026 08:00:00 -0400 A.06822034 CVM O.02168038 O.20026344 http://www.streetinsider.com/Press+Releases/CEL-SCI+to+Launch+FDA+Registration-Enabling+Phase+3+Confirmatory+Study+to+Bring+Multikine%C2%AE+to+Market+for+Newly+Diagnosed+Head+and+Neck+Cancer/26760011.html <ul class="bwlistdisc"> <li> <i>Patient enrollment expected to commence at clinical centers in the U.S., Europe, Asia and later on in South America</i> </li> <li> <i>The 212-patient confirmatory study is powered at approximately 97% to confirm a previously observed 0.34 hazard ratio, representing a 66% reduction in the risk of death</i> </li> <li> <i>In the target population, Multikine followed by standard of care increased the 5-year survival rate to 73% versus 45% with standard of care alone</i> </li> <li> <i>Pre-surgical tumor responses will be assessed and may serve as the basis for an early conditional or accelerated approval application with the FDA</i> </li> </ul> <p> VIENNA, Va.--(BUSINESS WIRE)-- CEL-SCI Corporation <b>(NYSE American: CVM)</b> http://www.streetinsider.com/Press+Releases/CEL-SCI+to+Launch+FDA+Registration-Enabling+Phase+3+Confirmatory+Study+to+Bring+Multikine%C2%AE+to+Market+for+Newly+Diagnosed+Head+and+Neck+Cancer/26760011.html Mon, 13 Jul 2026 08:00:00 -0400 A.06822034 CVM O.02168038 O.20026344 http://www.streetinsider.com/Press+Releases/CEL-SCI+to+Launch+FDA+Registration-Enabling+Phase+3+Confirmatory+Study+to+Bring+Multikine%C2%AE+to+Market+for+Newly+Diagnosed+Head+and+Neck+Cancer/26760011.html <ul class="bwlistdisc"> <li> <i>Patient enrollment expected to commence at clinical centers in the U.S., Europe, Asia and later on in South America</i> </li> <li> <i>The 212-patient confirmatory study is powered at approximately 97% to confirm a previously observed 0.34 hazard ratio, representing a 66% reduction in the risk of death</i> </li> <li> <i>In the target population, Multikine followed by standard of care increased the 5-year survival rate to 73% versus 45% with standard of care alone</i> </li> <li> <i>Pre-surgical tumor responses will be assessed and may serve as the basis for an early conditional or accelerated approval application with the FDA</i> </li> </ul> <p> VIENNA, Va.--(BUSINESS WIRE)-- CEL-SCI Corporation <b>(NYSE American: CVM)</b> http://www.streetinsider.com/Press+Releases/CEL-SCI+to+Launch+FDA+Registration-Enabling+Phase+3+Confirmatory+Study+to+Bring+Multikine%C2%AE+to+Market+for+Newly+Diagnosed+Head+and+Neck+Cancer/26760011.html Mon, 13 Jul 2026 08:00:00 -0400 A.06822034 CVM O.02168038 O.20026344 http://www.streetinsider.com/Business+Wire/CEL-SCI+to+Launch+FDA+Registration-Enabling+Phase+3+Confirmatory+Study+to+Bring+Multikine%C2%AE+to+Market+for+Newly+Diagnosed+Head+and+Neck+Cancer/26760011.html <ul class="bwlistdisc"> <li> <i>Patient enrollment expected to commence at clinical centers in the U.S., Europe, Asia and later on in South America</i> </li> <li> <i>The 212-patient confirmatory study is powered at approximately 97% to confirm a previously observed 0.34 hazard ratio, representing a 66% reduction in the risk of death</i> </li> <li> <i>In the target population, Multikine followed by standard of care increased the 5-year survival rate to 73% versus 45% with standard of care alone</i> </li> <li> <i>Pre-surgical tumor responses will be assessed and may serve as the basis for an early conditional or accelerated approval application with the FDA</i> </li> </ul> <p> VIENNA, Va.--(BUSINESS WIRE)-- CEL-SCI Corporation <b>(NYSE American: CVM)</b> http://www.streetinsider.com/Business+Wire/CEL-SCI+to+Launch+FDA+Registration-Enabling+Phase+3+Confirmatory+Study+to+Bring+Multikine%C2%AE+to+Market+for+Newly+Diagnosed+Head+and+Neck+Cancer/26760011.html Mon, 13 Jul 2026 08:00:00 -0400 A.06822034 CVM O.02168038 O.20026344 http://www.streetinsider.com/Business+Wire/CEL-SCI+to+Launch+FDA+Registration-Enabling+Phase+3+Confirmatory+Study+to+Bring+Multikine%C2%AE+to+Market+for+Newly+Diagnosed+Head+and+Neck+Cancer/26760011.html <ul class="bwlistdisc"> <li> <i>Patient enrollment expected to commence at clinical centers in the U.S., Europe, Asia and later on in South America</i> </li> <li> <i>The 212-patient confirmatory study is powered at approximately 97% to confirm a previously observed 0.34 hazard ratio, representing a 66% reduction in the risk of death</i> </li> <li> <i>In the target population, Multikine followed by standard of care increased the 5-year survival rate to 73% versus 45% with standard of care alone</i> </li> <li> <i>Pre-surgical tumor responses will be assessed and may serve as the basis for an early conditional or accelerated approval application with the FDA</i> </li> </ul> <p> VIENNA, Va.--(BUSINESS WIRE)-- CEL-SCI Corporation <b>(NYSE American: CVM)</b> http://www.streetinsider.com/Business+Wire/CEL-SCI+to+Launch+FDA+Registration-Enabling+Phase+3+Confirmatory+Study+to+Bring+Multikine%C2%AE+to+Market+for+Newly+Diagnosed+Head+and+Neck+Cancer/26760011.html Mon, 13 Jul 2026 08:00:00 -0400 A.06822034 CVM O.02168038 O.20026344 http://www.streetinsider.com/Business+Wire/CEL-SCI+to+Launch+FDA+Registration-Enabling+Phase+3+Confirmatory+Study+to+Bring+Multikine%C2%AE+to+Market+for+Newly+Diagnosed+Head+and+Neck+Cancer/26760011.html <ul class="bwlistdisc"> <li> <i>Patient enrollment expected to commence at clinical centers in the U.S., Europe, Asia and later on in South America</i> </li> <li> <i>The 212-patient confirmatory study is powered at approximately 97% to confirm a previously observed 0.34 hazard ratio, representing a 66% reduction in the risk of death</i> </li> <li> <i>In the target population, Multikine followed by standard of care increased the 5-year survival rate to 73% versus 45% with standard of care alone</i> </li> <li> <i>Pre-surgical tumor responses will be assessed and may serve as the basis for an early conditional or accelerated approval application with the FDA</i> </li> </ul> <p> VIENNA, Va.--(BUSINESS WIRE)-- CEL-SCI Corporation <b>(NYSE American: CVM)</b> http://www.streetinsider.com/Business+Wire/CEL-SCI+to+Launch+FDA+Registration-Enabling+Phase+3+Confirmatory+Study+to+Bring+Multikine%C2%AE+to+Market+for+Newly+Diagnosed+Head+and+Neck+Cancer/26760011.html Mon, 13 Jul 2026 08:00:00 -0400 A.06822034 CVM O.02168038 O.20026344 http://www.streetinsider.com/Business+Wire/CEL-SCI+to+Launch+FDA+Registration-Enabling+Phase+3+Confirmatory+Study+to+Bring+Multikine%C2%AE+to+Market+for+Newly+Diagnosed+Head+and+Neck+Cancer/26760011.html <ul class="bwlistdisc"> <li> <i>Patient enrollment expected to commence at clinical centers in the U.S., Europe, Asia and later on in South America</i> </li> <li> <i>The 212-patient confirmatory study is powered at approximately 97% to confirm a previously observed 0.34 hazard ratio, representing a 66% reduction in the risk of death</i> </li> <li> <i>In the target population, Multikine followed by standard of care increased the 5-year survival rate to 73% versus 45% with standard of care alone</i> </li> <li> <i>Pre-surgical tumor responses will be assessed and may serve as the basis for an early conditional or accelerated approval application with the FDA</i> </li> </ul> <p> VIENNA, Va.--(BUSINESS WIRE)-- CEL-SCI Corporation <b>(NYSE American: CVM)</b> http://www.streetinsider.com/Business+Wire/CEL-SCI+to+Launch+FDA+Registration-Enabling+Phase+3+Confirmatory+Study+to+Bring+Multikine%C2%AE+to+Market+for+Newly+Diagnosed+Head+and+Neck+Cancer/26760011.html Mon, 13 Jul 2026 08:00:00 -0400 A.06822034 CVM O.02168038 O.20026344 http://www.streetinsider.com/SEC+Filings/Form++ARS++++++++CEL+SCI+CORP++++++++++++++For%3A+Sep+30/26729375.html si-local-file:///var/storage/secattach/20260702/26729375.html http://www.streetinsider.com/SEC+Filings/Form++ARS++++++++CEL+SCI+CORP++++++++++++++For%3A+Sep+30/26729375.html Thu, 02 Jul 2026 17:08:00 -0400 CVM O.02168038 http://www.streetinsider.com/SEC+Filings/Form++ARS++++++++CEL+SCI+CORP++++++++++++++For%3A+Sep+30/26729375.html si-local-file:///var/storage/secattach/20260702/26729375.html http://www.streetinsider.com/SEC+Filings/Form++ARS++++++++CEL+SCI+CORP++++++++++++++For%3A+Sep+30/26729375.html Thu, 02 Jul 2026 17:08:00 -0400 CVM O.02168038 http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++CEL+SCI+CORP++++++++++++++For%3A+Jun+23/26729251.html si-local-file:///var/storage/secattach/20260702/26729251.html http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++CEL+SCI+CORP++++++++++++++For%3A+Jun+23/26729251.html Thu, 02 Jul 2026 17:02:00 -0400 CVM O.02168038 http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++CEL+SCI+CORP++++++++++++++For%3A+Jun+23/26729251.html si-local-file:///var/storage/secattach/20260702/26729251.html http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++CEL+SCI+CORP++++++++++++++For%3A+Jun+23/26729251.html Thu, 02 Jul 2026 17:02:00 -0400 CVM O.02168038 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++CEL+SCI+CORP++++++++++++++For%3A+Jun+30++Filed+by%3A+TALOR+EYAL/26717519.html si-local-file:///var/storage/secattach/20260701/26717519.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++CEL+SCI+CORP++++++++++++++For%3A+Jun+30++Filed+by%3A+TALOR+EYAL/26717519.html Wed, 01 Jul 2026 08:41:00 -0400 CVM O.02168038 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++CEL+SCI+CORP++++++++++++++For%3A+Jun+30++Filed+by%3A+TALOR+EYAL/26717519.html si-local-file:///var/storage/secattach/20260701/26717519.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++CEL+SCI+CORP++++++++++++++For%3A+Jun+30++Filed+by%3A+TALOR+EYAL/26717519.html Wed, 01 Jul 2026 08:41:00 -0400 CVM O.02168038 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++CEL+SCI+CORP++++++++++++++For%3A+Jun+30++Filed+by%3A+PRICHEP+PATRICIA++B/26717488.html si-local-file:///var/storage/secattach/20260701/26717488.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++CEL+SCI+CORP++++++++++++++For%3A+Jun+30++Filed+by%3A+PRICHEP+PATRICIA++B/26717488.html Wed, 01 Jul 2026 08:38:00 -0400 CVM O.02168038 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++CEL+SCI+CORP++++++++++++++For%3A+Jun+30++Filed+by%3A+PRICHEP+PATRICIA++B/26717488.html si-local-file:///var/storage/secattach/20260701/26717488.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++CEL+SCI+CORP++++++++++++++For%3A+Jun+30++Filed+by%3A+PRICHEP+PATRICIA++B/26717488.html Wed, 01 Jul 2026 08:38:00 -0400 CVM O.02168038 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++CEL+SCI+CORP++++++++++++++For%3A+Jun+30++Filed+by%3A+KERSTEN+GEERT+R/26717464.html si-local-file:///var/storage/secattach/20260701/26717464.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++CEL+SCI+CORP++++++++++++++For%3A+Jun+30++Filed+by%3A+KERSTEN+GEERT+R/26717464.html Wed, 01 Jul 2026 08:33:00 -0400 CVM O.02168038 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++CEL+SCI+CORP++++++++++++++For%3A+Jun+30++Filed+by%3A+KERSTEN+GEERT+R/26717464.html si-local-file:///var/storage/secattach/20260701/26717464.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++CEL+SCI+CORP++++++++++++++For%3A+Jun+30++Filed+by%3A+KERSTEN+GEERT+R/26717464.html Wed, 01 Jul 2026 08:33:00 -0400 CVM O.02168038 http://www.streetinsider.com/Corporate+News/CEL-SCI+signs+distribution+deal+with+Saudi+Amarox+for+cancer+drug/26682377.html <p>CEL-SCI Corporation (NYSE American: CVM) announced it signed an agreement with Saudi Amarox at the BIO International Convention 2026 on June 22 in San Diego, covering regulatory, marketing, distribution, and revenue sharing for its investigational cancer therapy Multikine in Saudi Arabia.</p> <p>Under the agreement, Amarox will support the planned introduction and commercialization of Multikine in Saudi Arabia, with an option to extend to other Gulf Cooperation Council countries, subject to regulatory approvals. Multikine has not been approved by the FDA or any other regulatory agency, and its safety and efficacy have not been established for any use.</p> <p>Multikine is an investigational cancer http://www.streetinsider.com/Corporate+News/CEL-SCI+signs+distribution+deal+with+Saudi+Amarox+for+cancer+drug/26682377.html Wed, 24 Jun 2026 08:00:34 -0400 A.29253873 CVM O.02168038 O.36700187 http://www.streetinsider.com/Corporate+News/CEL-SCI+signs+distribution+deal+with+Saudi+Amarox+for+cancer+drug/26682377.html <p>CEL-SCI Corporation (NYSE American: CVM) announced it signed an agreement with Saudi Amarox at the BIO International Convention 2026 on June 22 in San Diego, covering regulatory, marketing, distribution, and revenue sharing for its investigational cancer therapy Multikine in Saudi Arabia.</p> <p>Under the agreement, Amarox will support the planned introduction and commercialization of Multikine in Saudi Arabia, with an option to extend to other Gulf Cooperation Council countries, subject to regulatory approvals. Multikine has not been approved by the FDA or any other regulatory agency, and its safety and efficacy have not been established for any use.</p> <p>Multikine is an investigational cancer http://www.streetinsider.com/Corporate+News/CEL-SCI+signs+distribution+deal+with+Saudi+Amarox+for+cancer+drug/26682377.html Wed, 24 Jun 2026 08:00:34 -0400 A.29253873 CVM O.02168038 O.36700187 http://www.streetinsider.com/Corporate+News/CEL-SCI+signs+distribution+deal+with+Saudi+Amarox+for+cancer+drug/26682377.html <p>CEL-SCI Corporation (NYSE American: CVM) announced it signed an agreement with Saudi Amarox at the BIO International Convention 2026 on June 22 in San Diego, covering regulatory, marketing, distribution, and revenue sharing for its investigational cancer therapy Multikine in Saudi Arabia.</p> <p>Under the agreement, Amarox will support the planned introduction and commercialization of Multikine in Saudi Arabia, with an option to extend to other Gulf Cooperation Council countries, subject to regulatory approvals. Multikine has not been approved by the FDA or any other regulatory agency, and its safety and efficacy have not been established for any use.</p> <p>Multikine is an investigational cancer http://www.streetinsider.com/Corporate+News/CEL-SCI+signs+distribution+deal+with+Saudi+Amarox+for+cancer+drug/26682377.html Wed, 24 Jun 2026 08:00:34 -0400 A.29253873 CVM O.02168038 O.36700187